Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

  • Post published:October 20, 2020
  • Post category:Press Release
Read more about the article Havn Announces Appointments of Vic Neufeld and Rick Brar to Board; Accelerates Warrants

Havn Announces Appointments of Vic Neufeld and Rick Brar to Board; Accelerates Warrants

  • Post published:October 5, 2020
  • Post category:Press Release
Read more about the article Havn Life Sciences Granted Section 56 Exemption to Begin Scientific Work With Psilocybin

Havn Life Sciences Granted Section 56 Exemption to Begin Scientific Work With Psilocybin

  • Post published:September 10, 2020
  • Post category:Press Release
Read more about the article Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE

Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE

  • Post published:September 8, 2020
  • Post category:Press Release
Read more about the article Havn Life Sciences Announces Filing of Final Prospectus and Conditional Approval for Listing on CSE

Havn Life Sciences Announces Filing of Final Prospectus and Conditional Approval for Listing on CSE

  • Post published:September 3, 2020
  • Post category:Press Release
Read more about the article Havn Life Sciences Inc. Announces Appointment of Gary Leong as Chief Science Officer

Havn Life Sciences Inc. Announces Appointment of Gary Leong as Chief Science Officer

  • Post published:July 6, 2020
  • Post category:Press Release
Read more about the article Havn Life Sciences Inc. Announces Launch & Filing of Preliminary Prospectus

Havn Life Sciences Inc. Announces Launch & Filing of Preliminary Prospectus

  • Post published:June 25, 2020
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More